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Dermal fibroblasts (dFBs) resist infection by locally
differentiating into adipocytes and producing cathe-
licidin antimicrobial peptide in response to Staphylo-
coccus aureus (S. aureus). Here, we show that
neonatal skin was enriched with adipogenic dFBs
and immature dermal fat that highly expressed cath-
elicidin. The pool of adipogenic and antimicrobial
dFBs declined after birth, leading to an age-depen-
dent loss of dermal fat and a decrease in adipogene-
sis and cathelidicin production in response to infec-
tion. Transforming growth factor beta (TGF-b),
which acted on uncommitted embryonic and adult
dFBs and inhibited their adipogenic and antimicro-
bial function, was identified as a key upstream regu-
lator of this process. Furthermore, inhibition of the
TGF-b receptor restored the adipogenic and antimi-
crobial function of dFBs in culture and increased
resistance of adult mice to S. aureus infection. These
results provide insight into changes that occur in the
skin innate immune system between the perinatal
and adult periods of life.
INTRODUCTION
Staphylococcus aureus (S. aureus) is responsible for the majority
of skin and soft-tissue infections in humans, and MRSA (methi-
cillin-resistant S. aureus) infections over the past two decades
were responsible for more deaths in the United States than any
other pathogen (Klein et al., 2007;Miller and Cho, 2011). It is diffi-
cult to treat S. aureus infections because of its evolved resis-
tance to common antibiotics; therefore, a better understanding
of skin host defense mechanisms against S. aureus is acutelyneeded for developing strategies to combat this important public
health problem.
Skin provides a physical and immunological barrier protecting
internal tissues from external insults. Dermal white adipose tis-
sue (dWAT) is the deepest barrier of the skin and an understudied
fat depot compared with inguinal white adipose tissue (iWAT)
and epididymal white adipose tissue (eWAT) (Zwick et al.,
2018). Until recently, dWAT was thought to function merely as
an energy reservoir and a thermo-insulating layer. Recent
studies, however, have revealed that dWAT also plays active
roles in various physiological and pathological processes, such
as the regeneration of hair follicles (Festa et al., 2011), wound
healing (Plikus et al., 2017; Schmidt and Horsley, 2013), thermo-
genesis (Kasza et al., 2014), skin fibrosis (Marangoni et al., 2015),
and protection against skin infection (Zhang et al., 2015). dWAT
is produced by a subpopulation of dermal fibroblasts (dFBs).
dFBs are a major skin cell type that has considerable functional
diversity (Philippeos et al., 2018; Tabib et al., 2018). The reticular
dermis contains dFBs with adipocyte progenitor properties,
and these cells can commit to preadipocytes (pAds) and differ-
entiate into adipocytes (ADs) upon stimulation (Driskell et al.,
2013; Festa et al., 2011; Schmidt and Horsley, 2013; Zhang
et al., 2015).
S. aureus skin infection triggers the rapid and localized differ-
entiation of pAds to ADs, and we refer to this process as reactive
adipogenesis. Reactive adipogenesis is characterized by the
proliferation of adipocyte progenitor cells expressing preadipo-
cyte factor 1 (PREF1) and is followed by their differentiation
into immature ADs (Zhang et al., 2015). During this process,
cathelicidin antimicrobial peptide (Camp) is abundantly ex-
pressed during the immature AD stage of differentiation. This
expression of Camp is necessary to limit bacterial spread
because the inhibition of this adipogenic-antimicrobial function
of immature ADs leads to increased susceptibility to S. aureus
infection (Zhang et al., 2015).
In this study, we sought to better understand the regulation of
reactive adipogenesis in skin innate immunity. To explore thisImmunity 50, 121–136, January 15, 2019 ª 2018 Elsevier Inc. 121
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Figure 1. Dermal PDGFRA+THY1hi Adipocyte Progenitors and Their Antimicrobial Response Are Lost with Advancing Age
(A) Schematic representation of the mouse Camp locus with exons 2–4 flanked by LoxP sites. The inset gel image represents the genotyping result of WT (+/+),
heterozygote (f/+), and homozygous mutant (f/f) mice by using primers flanking Camp as indicated.
(B) Campf/f (WT) or Campf/fPdgfra-cre (Campf/f;Pdgfra-cre) littermate mice (2 months of age) were infected intradermally (i.d.) with S. aureus, and Camp mRNA
expression (ratio to housekeeping gene Tbp) in skin or spleen tissues was measured by qRT-PCR analyses (n = 3–5 per group).
(C) Measurement of bacterial CFU from the infection edge area of the skin from infected Campf/f or Campf/fPdgfra-cre mice (n = 6 per group).
(legend continued on next page)
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question, we investigated changes in adipogenic function of
dFBs during embryonic and adult development inmouse and hu-
man skin. A decrease in the capacity of dFBs to differentiate into
adipocytes and express cathelicidin was observed to occur after
birth and during the adult period of life. Furthermore, transform-
ing growth factor beta (TGF-b) was identified to induce the loss of
adipogenic potential and antimicrobial function of dFBs. These
results uncover a previously unknown mechanism that impairs
innate immune defense of the skin.
RESULTS
Dermal PDGFRA+THY1hi Adipocyte Progenitors and
Their Antimicrobial Response Are Lost with
Advancing Age
To establish the contribution of adipocyte-lineage cells com-
pared with non-adipocyte-lineage cells to cathelicidin expres-
sion, we generated mice to permit conditional deletion of
Camp by inserting LoxP sites flanking exons 2–4 (Figure 1A).
We crossed these Campflox/flox mice with Pdgfra-cre or
Adipoq-cre mice to delete Camp in dFBs that express Pdgfra
(Campf/fPdgfra-cre) or cells that express Adipoq (Campf/f
Adipoq-cre) in the later pAD stage. Flow cytometry and qRT-
PCR validated that Pdgfra or cre expression was highly enriched
in THY1+CD45 dFBs, but not in THY1CD45+ myeloid immune
cells or spleen tissue (Figures S1A and S1B). Upon S. aureus
infection, Camp expression was significantly suppressed in the
Campf/fPdgfra-cre and Campf/fAdipoq-cre skin, but not in the
spleen or blood cells (Figures 1B and S1C–S1E). Campf/f
Pdgfra-cre and Campf/fAdipoq-cre mice became significantly
more susceptible to S. aureus infection than wild-type (WT) litter-
mate controls (Figures 1C and S1F–S1H). These results reinforce
the conclusion that cathelicidin derived from cells of the adipo-
cyte lineage plays a role in defense against S. aureus infection.
In general, innate immune defense is maximal in late fetal and
early postnatal life and declines with age (Futata et al., 2012;
Georgountzou and Papadopoulos, 2017; Shaw et al., 2013). An
age-dependent decrease in the ability of skin to clear bacteria
was evident by increased bacterial colony-forming units (CFU)
in the infection edge area with advancing age (Figures 1D and
S1I). To understand the contribution of adipogenesis to this
loss of innate immune defense, we next examined the expres-
sion of cathelicidin in the cells of the adipocyte lineage during ag-(D) 3-week-old, 2-month-old, 1-year-old, or 2-year-old WTmice were infected i.d.
area (n = 4–5 per group).
(E) Cathelicidin (red) and COLIV (green) immunohistochemistry staining in contr
stained with DAPI (blue). Scale bars, 100 mm.
(F) qRT-PCR of Camp or Spp1 expression in S. aureus-infected skin or control s
(G) Flow-cytometry plots for gating strategies for dermal PDGFRA+THY1hi adipo
(H) Flow-cytometry quantification of the geometric mean fluorescence intensity (g
control or S. aureus-infected skin (n = 3 per group).
(I) Flow-cytometry plots of THY1 and PDGFRA in CD31CD45PDGFRA+ FBs in
(J) Overlaid histogram of THY1 expression in CD31CD45-PDGFRA+ FBs in skin
(K) Stacked bar graphs showing age-dependent changes of the percentage of THY
eWAT (average of n = 3 per group).
(L) Age-dependent changes of the percentage of THY1lo–medPDGFRA+ fibroblas
neutrophils, CD11C+F4/80 dendritic cells, CD45+TCRgd+ T cells, and CD45+TC
per group).
All error bars indicate mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 (one-waying. A progressive loss of the capacity of S. aureus to trigger
reactive adipogenesis was observed with advancing age, as
measured by lesser staining of cathelicidin (Figure 1E) and lower
expression of Pref1 and Camp mRNA (Figures S1J and 1F) in
dWAT at sites of infection. Loss of dermal reactive adipogenesis
in response to S. aureus correlated with an age-dependent in-
crease in the mRNA expression of Spp1, a pro-fibrotic marker
(Figure 1F).
Next, we established a flow-cytometry method to define dFB
cell populations that are activated upon S. aureus infection. Adi-
pogenic dFBs were gated as CD31;CD45;PDGFRA+;THY1hi
cells (Chia et al., 2016; Rivera-Gonzalez et al., 2016). S. aureus
infection triggered an increase in surface expression of PDGFRA
and Sca1 in THY1hi;PDGFRA+ cells, but not in THY1lo;PDGFRA+
cells (Figures 1G, 1H, and S1K). This suggested that reactive adi-
pogenesis was restricted to THY1hi dFBs. To determine whether
age-related loss of reactive adipogenesis was associated with
the loss of THY1hi dFBs, we analyzed THY1 expression in
PDGFRA+ dFBs in the late embryos and in mice up to 2 years
of age. Fibroblasts from eWAT were also analyzed because
eWAT has been previously reported to have age-associated
dysfunction in adipogenesis and increased production of pro-in-
flammatory cytokines and fibrotic features (Kirkland et al., 1993;
Sun et al., 2013). Flow-cytometry analyses revealed that
PDGFRA+ fibroblasts in eWAT progressively lost THY1 expres-
sion with advancing age (from 3 weeks, 2 months, and 1 year
to 2 years old), and by 1–2 years of age, PDGFRA+ fibroblasts
in eWAT were mostly THY1lo (Figures 1I–1K). In the skin, embry-
onic day 14 (E14) PDGFRA+ dFBs were mostly THY1lo (>97%)
and became mostly THY1hi (>90%) by postnatal day 1 (P1).
Similar to that in eWAT, THY1 expression in dermal PDGFRA+ fi-
broblasts then became progressively lost during postnatal
development and aging (Figures 1I–1K). Thus, age-related loss
of THY1 expression is a common feature of PDGFRA+ fibroblasts
in both eWAT and skin.
Next, age-related changes in PDGFRA+ dFBs were evaluated
in parallel with changes in myeloid- or lymphoid-derived immune
cells, including CD11B+F4/80+ macrophages, CD11B+Ly6Ghi
neutrophils, CD11C+F4/80 dendritic cells (DCs), CD45+ T cell
receptor (TCR)gd+ T cells and CD45+TCRab+ T cells (Figures
1L, S1M, and S1N). PDGFRA+THY1hi dFBs represented the ma-
jor resident innate cell type (75% of total dermal cells) in
neonatal (P1) skin. During postnatal development (at 3 weekswith S. aureus, and bacteria CFU count was measured from the infection edge
ol or S. aureus-infected skin (representative of n = 3 per group). Nuclei were
kin (ratio to Tbp) (n = 3–5 per group).
cyte progenitors (representative of n = 3 per group).
MFI) of Sca1 expression in THY1lo or THY1hi CD31CD45PDGFRA+ dFBs in
skin dermis or eWAT (representative of n = 3 per group).
dermis or eWAT (representative of n = 3 per group).
1lo, THY1med, and THY1hi cells in CD31CD45-PDGFRA+ FBs in skin dermis or
ts, THY1hiPDGFRA+ fibroblasts, CD11B+F4/80+ macrophages, CD11B+Ly6G+
Rab+ T cells in the total dermal cell population as indicated (average of n = 3
ANOVA). Please also see Figure S1.
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and 2 months of age), the decline in THY1hi dFBs was accompa-
nied by an increase in myeloid-derived immune cell populations.
Upon aging (at 1 or 2 years of age), the THY1hi dFB population
continued to decline, as did macrophages and DCs, whereas
CD45+TCRab+ cells increased both in the skin and in eWAT (Fig-
ures 1L, S1M, and S1N).
Next, we characterizedwhether age-related changes in adipo-
genic dFBs correlated with changes in dermal fibrogenesis and
adipogenesis. As shown in Figure 2A, whereas dWAT and the fi-
brogenic features (collagen staining and dermal hydroproline
content) of the dermis were not developed in E14 skin, neonatal
skin featured a large volume of dWAT with immature adipocytes
and numerous small lipid droplets (Figures 2A, 2B, and S2A).
Dermal adipocytes matured (indicated by large lipid droplets)
by 3 weeks of age and were then gradually lost during adulthood
and aging (from 2 months to 2 years of age) (Figure 2A). Loss of
immature dermal fat with advancing age was also supported by
an early peak at P1 in the mRNA expression of Pref1 and Camp,
genes associated with early adipogenesis, and their subsequent
progressive decline from postnatal development through aging
(Figures 2C and 2D). Immunostaining for cathelicidin confirmed
that it was abundantly expressed by P1 immature dermal ADs,
whereas its expression was decreased in mature 3-week-old
ADs and became undetectable in the 1-year-old ADs (Fig-
ure S2B). Deletion of Camp in Pdgfra+ dFBs (Campf/fPdgfra-
cre) or Adipoq+ ADs (Campf/fAdipoq-cre) led to a >95% and
75% reduction in Camp mRNA expression in neonatal skin,
respectively (Figure 2E), confirming that differentiating immature
ADs are the major cellular source of cathelicidin in neonatal skin.
The expression of mature adipocyte markers, including Adipoq
and Fabp4, peaked from 3 weeks to 2 months of age and then
decreased progressively from 2 months to 2 years of age (Fig-
ures 2C and S2C), supporting our histological observation that
mature ADs were lost with age. Age-dependent loss of immature
dermal fat coincided with an age-dependent gain in dermal
fibrotic features, especially in the dWAT layer, as shown by
collagen staining, hydroxyproline measurement, and Col1a1
mRNA expression (Figures 2A–2C and S2D). Elastic fibers in
dFBs also developed postnatally, and they became less dense
in the lower dermis with advancing age (Figure S2A). By 2 years
of age, the dermis appeared thinner and Col1a1 mRNA expres-
sion was low (Figures 2A and S2D), and the dWAT layer becameFigure 2. Loss of Dermal Immature Fat and Adipogenic-Antimicrob
Mouse Skin
(A) Gomori Trichrome staining (top) or lipid BODIPY (green) and phalloidin (red) sta
n = 3–6 per group).
(B) Hydroxyproline content (mg per mg of tissue) in mouse dorsal skin at the indi
(C) Heatmap showing the mRNA expression kinetics of listed pAd or AD genes i
(D) Camp mRNA expression kinetics in mouse skin at the indicated age (n = 3 pe
(E) Relative Camp mRNA expression in skin isolated from neonatal Campf/f, Cam
(F) Phase-contrast images showing age-dependent alterations in the adipogenic
(G) Phase-contrast images showing time-course adipocyte differentiation from n
(H) Heatmap showing kinetics of pAd or AD gene mRNA expression during adip
(I) Bar graphs of mRNA expression kinetics of Camp or Col1a1 during adipocyte
(J) Camp or Col1a1 mRNA expression in undifferentiated dFBs or differentiated
(K) Image of SA113 or USA300 growth on an agar plate or CFU count of bacterial
(n = 3 per group).
(L and M) Growth curve (L) or CFU count (M) of S. aureus in CM from undifferentia
All error bars indicate mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 (one-waydevoid of ADs and showed extensive collagen staining (Figures
2A and S2A). Altogether, these results show that age-dependent
loss of adipogenic dFBs is associated with a progressive loss of
immature dermal fat and gain of fibrotic features.
To define adipogenic potential of the cells associated with the
age-related changes observed in mouse skin, we isolated dFBs
from skin at various ages and differentiated them into adipocytes
in vitro. Whereas uncommitted E14 dFBs were only partially
adipogenic, neonatal P1 dFBs were highly adipogenic, and this
adipogenic potential gradually declined during postnatal devel-
opment (from 3 weeks to 2 months of age) and was lost in
1-year-old dFBs (Figure 2F). Time-course analysis of differenti-
ating neonatal dFBs showed that immature ADs with small lipid
droplets were formed as early as post-differentiation day 2
(PD2), and by PD4PD7, >90% of cells became mature ADs
with large lipid droplets (Figure 2G). Gene expression analyses
revealed four distinct expression kinetics: (1) Col1a1 and Thy1
mRNA expression was highest in undifferentiated cells and grad-
ually decreased as cells converted to ADs; (2) Pdgfra, Sca1,
Pref1, or Pparg1 mRNA expression was detected prior to differ-
entiation, was further elevated on PD1PD2, and then robustly
decreased at PD4; (3) Camp expression was induced as early
as PD1 and peaked around PD2; and (4) Pparg2, Adipoq, or
Fabp4 mRNA expression was induced later, around PD2PD4,
and continued to increase as adipocytes matured (Figures 2H
and 2I). Campf/fPdgfra-cre dFBs or Campf/fAdipoq-cre dFBs
showed loss ofCamp expression and secretion through differen-
tiation in vitro (Figures S2E–S2G), confirming that these adipose
precursor cells are the major cellular source of cathelicidin. The
ability of differentiating neonatal dFBs to express Camp and
Pparg2 mRNA (Figures 2J and S2H) and to secrete cathelicidin
protein into conditioned medium (Figures S2I and S2J) was pro-
gressively lost in dFBs isolated from 3-week-old, 2-month-old,
and 1-year-old skin. In contrast, adult dFBs produced higher
Col1a1 mRNA expression during differentiation than neonatal
dFBs (Figure 2J), suggesting that decreased adipogenic function
is accompanied by increased fibrogenic function in adult dFBs.
Functionally, the supernatant from differentiating P1 dFBs
potently inhibited the growth of S. aureus (SA113 and USA300)
(Figure 2K), whereas the age-related decline in antimicrobial pro-
tein expression correlated with decreased capacity of differenti-
ating dFBs to inhibit the growth of S. aureus (Figures S2L andial Function of Primary dFBs during Development and Aging of
ining (bottom) of skin sections frommice at the indicated age (representative of
cated age (representative of n = 3 per group).
n mouse skin at the indicated age (average of n = 3 per group).
r group).
pf/fPdgfra-cre, or Campf/f;Adipoq-cre neonatal littermates (n = 3 per group).
potential of primary dFBs (representative of n = 3 per group).
eonatal P1 dFBs (representative of n = 3 per group).
ocyte differentiation of P1 dFBs (average of n = 3 per group).
differentiation of P1 dFBs (average of n = 3 per group).
adipocytes (n = 3–5 per group).
growth in conditioned medium from P1 ADs or undifferentiated cells or DMEM
ted dFBs or differentiated adipocytes at the indicated age (n = 3–5 per group).
ANOVA). Scale bars, 100 mm. Please also see Figure S2.
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S2M). Altogether, these data show a loss of immature dermal fat
and that the adipogenic-antimicrobial function of dFBs occurs
with age.
Activation of the TGF-b Pathway Is Associated with the
Loss of Antimicrobial Function of dFBs
To better understand the change in the antimicrobial and adipo-
genic functions of dFBs, we profiled the transcriptomes of pri-
mary dFBs isolated at different ages by RNA sequencing
(RNA-seq). Because fibroblast populations become heteroge-
neous during postnatal development (Driskell et al., 2013) (Fig-
ure S3A), we sorted Sca1+ dFBs from all postnatal groups to
focus on the dFB population committed to the adipose lineage.
Sca1 labeling purity was confirmed by flow cytometry (Fig-
ure S3B), and compared with Sca1+ dFBs, sorted Sca1 dFBs
were confirmed to be unable to differentiate into ADs (Fig-
ure S3C). Because dFBs lost their adipogenic function by
2 months of age (Figure 2E), we chose 2 months as the most
advanced age group for RNA-seq analyses.
Principle-component analysis revealed a distinction in the
transcriptomes of dFBs isolated from different age groups. E14
dFBs and 2-month-old Sca1+ dFB samples were clearly sepa-
rated from P1 Sca1+ dFB samples (Figure 3A). Time-course
analyses identified seven gene clusters with multiple Gene
Ontologies (GOs) undergoing distinct temporal changes (Figures
3B and S3D–S3I). To identify top putative regulators that
drive these age-associated changes, we performed Ingenuity
Pathway Analysis (IPA) and identified TGF-b signaling as the
top activated signaling pathway in 2-month-old Sca1+ dFBs
compared with P1 Sca1+ dFBs (Figure 3C). IPA also predicted
that TGF-b signaling activities were significantly different be-
tween dFBs from other age groups and P1 Sca1+ dFBs (Figures
S3J and S3K). Consistently, RNA-seq and qRT-PCR analyses
(Figures 3D–3G) revealed that the expression of the key genes
in the TGFBR pathway, including Tgfbr1 or Tgfbr2, Tgfb1 or
Tgfb2, and Inhba, was higher in 2-month-old than in P1 Sca1+
dFBs. The expression of several TGF-b pro-fibrotic genes down-
stream of TGF-b, including Acta2 (coding for alpha smooth mus-
cle actin [SMA]), Ctgf, Spp1, Pai1, Mmp13, Saa3, and Il6, was
strongly elevated in 2-month-old cells compared with P1 cells.
In contrast, the expression of several pro-adipogenic genes,
including Pref1, Pparg, Sca1, Lpl (Gregoire et al., 1998), and
Dcn (a natural inhibitor of TGF-b signaling [Border et al., 1992]),
was suppressed in 2-month-old cells compared with P1 cells.
Similar to 2-month-old cells, E14 fibroblasts expressed and
secreted significantly higher amounts of Tgfb2 transcript and
TGF-b2 protein than neonatal dFBs (Figures 3E and 3F). The
expression of proadipogenic genes, including Pparg, Sca1,
and Dcn, was suppressed in E14 compared with P1 cells, but
profibrotic genes, including Acta2 and Spp1, were only moder-
ately elevated in E14 cells, suggesting that the pro-fibrotic effect
of TGF-b is preferentially suppressed in embryonic cells. Alto-
gether, these results indicate that TGF-b could play a role in
the age-related switch from pro-adipogenic to pro-fibrotic dFBs.
TGF-b2 Drives Loss of Adipogenic-Antimicrobial
Function in Neonatal dFBs
To determine whether the presence of TGF-b ligands is function-
ally relevant, we treated neonatal dFBs with recombinant mouse126 Immunity 50, 121–136, January 15, 2019TGF-b2. Doses as low as 0.1 ng/mL of TGF-b2 potently sup-
pressed the adipogenic function of P1 cells, and at higher doses
(3–10 ng/mL) it not only completely abolished adipogenic func-
tion but also triggered a fibrotic phenotype characterized by
extensive cell striation and spindle-shaped morphology (Fig-
ure 4A). In parallel, the induction of adipocyte marker genes,
secretion of cathelicidin and FABP4, and suppression of
Col1a1 mRNA upon adipocyte differentiation were inhibited by
TGF-b2 (Figures 4B and 4C). In undifferentiated P1 dFBs, TGF-
b2 triggered a dose-dependent decrease in the expression of
pro-adipogenic genes (Sca1, Pref1, Pparg1, and Dcn) and an in-
crease in the expression of pro-fibrotic and inflammatory genes
(Spp1, Acta2, Mmp13, Pai1, Ctgf, and Il6) (Figures 4D and 4E).
Similar results were also seen in neonatal dFBs treated with
TGF-b1, except that TGF-b1 was three to ten times less potent
than TGF-b2 (Figures S4A and S4B).
To characterize the dynamic interplay between pro-fibrotic and
anti-adipogenic functions of TGF-b, we evaluated expression of
Sca1 and SMA in PDGFRA+THY1+ dFBs by flow cytometry (Fig-
ure S4C). Cultured neonatal PDGFRA+THY1+ dFBs exhibited
high Sca1 and low SMA mRNA expression. Treatment with TGF-
b2 or TGF-b1 for 2 days led to a rapid dose-dependent decrease
inSca1and increase inSMAexpression (Figures4F,4G,andS4D).
Flow-cytometry analyses of cultured dFBs from various ages re-
vealed that,whereas neonatal PDGFRA+THY1+dFBsweremostly
Sca1hiSMAlo, dFBs gradually lost Sca1 and gained SMA expres-
sion with age, and by 1 year of age, most cells were Sca1loSMAhi
(Figures 4H and 4I). Cultured 2-month-old and 1-year-old dFBs
strongly resembled neonatal dFBs treated for 2 days with TGF-
b2 (Figure 4F). The antimicrobial activity of differentiating neonatal
dFBsagainstS.aureuswascompletely suppressedafter theaddi-
tion of TGF-b2 (Figures 4J, 4K, and S4E). These results demon-
strate that TGF-b2 is a potent suppressor of dFBs’ capacity to
differentiate into ADs and provide antimicrobial activity.
TGF-b Exerts Anti-adipogenic Effects on dFBs by
Activating the TGFBR-SMAD2/3 Pathway
To understand the signaling pathway mediating the effect of
TGF-b on dFBs, we evaluated downstream signaling molecules
of the TGF-b pathway. Phosphoblotting analyses of neonatal
dFBs treated with TGF-b2 showed that TGF-b2 induced a tran-
sient increase in SMAD2/3 and AKT phosphorylation (Figure 5A).
To determine the role of SMAD3 and AKT in the effects of TGF-b,
we applied small pharmacological inhibitors specific to SMAD3
(SIS3) (Jinnin et al., 2006), AKT (Wortmannin) (Zhang et al.,
2016), or TGFBR SB431542 (SB) (Inman et al., 2002; Mordasky
Markell et al., 2010). Pretreatment with either SMAD3 or TGFBR
inhibitors, but not an AKT inhibitor, rescued TGF-b-driven sup-
pression of Pparg1 and induction of CtgfmRNA expression (Fig-
ure 5B) and restored the adipogenic function and the ability of
neonatal dFBs to produce and secrete cathelicidin (Figures
5C–5D and S5A). These results demonstrate that TGF-b exerts
its pro-fibrotic and anti-adipogenic effects on dFBs via the
TGFBR-SMAD2/3 pathway.
Inhibition of TGFBR Function Boosts dFB Adipogenic
Potential and Enhances Resistance to Skin Infection
To test the hypothesis that TGF-b2 is responsible for the age-
dependent loss of adipogenic capacity of dFBs, we treated
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Figure 3. Activation of the TGF-b Pathway Is Associated with the Loss of Antimicrobial Function of dFBs
(A) Principle-component-analysis plot for RNA-seq shows differential clustering of E14, E17, or Sca1+ cells sorted into P1, 3-week-old, and 2-month-old dFBs.
Dots with the same color represent biological replicates in the indicated age group (n = 3 per age group).
(B) Time-course analyses by maSigPro identified seven gene clusters with distinct expression dynamics in dFBs from E14 to 2 months as indicated. The number
of genes in each cluster is indicated on the right.
(C) Ingenuity Pathway Analysis identified several signaling pathways that were activated (orange) or inhibited (blue) in 2-month-old Sca1+ dFBs comparedwith P1
Sca1+ dFBs. Respective log(p values), Z scores, and ratios are shown for each pathway. The calculated Z score indicates a pathway with genes exhibiting
overall increasedmRNA (orange bars) or decreasedmRNA (blue bars) expression. The ratio (orange dots connected by a line) indicates the ratio of dataset genes
that map to the pathway to the total number of genes that map to the same pathway, e.g., >15% for TGF-b signaling.
(D) Heatmap showing relative mRNA expression (based on RNA-seq-derived RPKM [reads per kilobase of transcript per million mapped reads] values) of a panel
of TGFBR pathway genes, pro-fibrotic genes, or pro-adipogenic genes in primary dFBs (average of n = 3 per group).
(E) qRT-PCR analyses showing mRNA expression of TGF-b-family genes (ratio to Tbp) in dFBs at the indicated ages (n = 3 per group).
(F) TGF-b2 secretion (pg/mL) in the conditioned medium of dFBs was quantified by ELISA (n = 3 per group).
(G) qRT-PCR analyses validating age-dependent changes in mRNA expression of pro-adipogenic genes (Pref1, Sca1, and Pparg1) or pro-fibrotic genes (Acta2,
Ctgf, and Spp1) (n = 3 per group).
All error bars indicate mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 (one-way ANOVA). Please also see Figure S3.primary dFBs isolated from mice of various ages with SB in cul-
ture for 3 days. Inhibition of TGFBR reversed the loss of Sca1 and
gain of SMA observed in PDGFRA+THY1+ dFBs during aging(Figures 5E–5G). The age-associated suppression of pro-adipo-
genic Pparg1 and increased expression of the pro-fibrotic Spp1
were also reversed by SB treatment (Figures 5H and 5I).Immunity 50, 121–136, January 15, 2019 127
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Figure 4. TGF-b2 Drives a Loss of Adipogenic-Antimicrobial Function of Neonatal dFBs
(A–C) Neonatal dFBswere treated with increasing doses of TGF-b2 and differentiated into adipocytes. (A) Phase-contrast images showing adipocyte formation at
day 4 (representative of n = 3 per group). Scale bars, 100 mm. (B) Heatmap showing the effect of TGF-b2 in suppressing themRNA expression of adipocyte genes
(average of n = 3 per group). (C) Camp mRNA expression was measured by qRT-PCR (top bar graphs) and CAMP and FABP4 secretion (lower western blots)
(representative of n = 3 per group).
(D–G) Neonatal P1 dFBs were treated with increasing doses of TGF-b2 for 2 days under undifferentiated conditioned. Heatmap (D) or bar graphs (E) show relative
expression of pro-adipogenic or pro-fibrotic genes as indicated (n = 3 per group). Also shown are flow-cytometry plots (F) or overlaid histograms (G) of Sca1 and
SMA (representative of n = 3 per group).
(H) Flow-cytometry plots of Sca1 and SMA in cultured PDGFRA+THY1+ dFBs at the indicated age.
(I) Overlaid histogram of the Sca1 or SMA expression shown in (H) (representative of n = 3 per group).
(J) Growth curve of USA300 in CM from undifferentiated dFBs or differentiated adipocytes (n = 3–5 per group). Inset phase-contrast images show the effect of
TGF-b2 in suppressing adipocyte formation. Scale bars, 100 mm.
(K) Bacterial growth image on agar plate or CFU count of USA300 growth at 20 hr in CM from adipocytes treated with or without TGF-b2 as indicated (n = 3–5
per group).
All error bars indicate mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 (one-way ANOVA). Please also see Figure S4.
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Figure 5. TGF-b Mediates Its Pro-fibrotic and Anti-adipogenic Function by Activating the TGFBR-SMAD2/3 Pathway in dFBs
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(legend continued on next page)
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Inhibition of TGFBR enabled embryonic and adult dFBs to differ-
entiate into mature adipocytes (Figure 5J) and express cathelici-
din (Figure 5K). Col1a1 expression was also suppressed upon
TGFBR inhibition (Figure S5B). Furthermore, the antimicrobial
potential of the conditioned medium from differentiating embry-
onic dFBs was enhanced when TGFBRwas inhibited (Figure 5L).
TGF-b Signaling Is Active in the Dermis and Promotes
Loss of Antimicrobial Defense in Mice
To investigate the role of the TGF-b pathway in dFBs in vivo, we
examined activation of phosph-SMAD2/3 (pSMAD2/3) and the
abundance of TGF-b in mice of various ages. Increased
pSMAD2/3 was seen in adult dermis (3 weeks to 2 years of age)
compared with neonatal dermis (Figure 6A). P1 and 3-week-old
skin showed random pSMAD2/3 distribution throughout the
dermis, whereas 2-month- to 2-year-old skin showed prominent
pSMAD2/3 staining in the dWAT layer (Figure 6A). This suggests
that pSMAD2/3 signals might be preferentially turned on only in
the committed pAds in dWAT during adulthood. Circulating
TGF-b2 concentrations in serum were high in neonatal (P1–P7)
and young adultmice (3weeks of age) but then declined progres-
sivelywith advancing age (2months to 2 years of age) (Figure 6B).
In contrast, circulating TGF-b1 concentrations were low in neo-
nates and became elevated from adulthood through aging (Fig-
ure 6C). To determine whether TGF-b might promote dermal fat
loss in adulthood, we treated adult mice intradermally with SB
for 5 days (Figure 6D). SB-treated skin showednotable expansion
of the dWAT layer (Figure 6D) and higher expression ofCamp and
Adipoq and lower expression of pro-fibrotic genes (Col1a1 and
Ctgf) than non-SB-treated skin (Figure 6E).
To determine whether these observations could translate into
reduced susceptibility to infection in vivo, we administrated SB
after infecting 1-year-old adult mouse skin with S. aureus strain
USA300 (Figure 6F). Treating the infectedmicewith SB improved
resistance to S. aureus skin infection, as shown by a decrease in
lesion size and bacterial CFU at the infection edge and in the
central area of the lesion (Figures 6F and 6G). qRT-PCR analyses
revealed that SB administration not only increased the expres-
sion of pAd- or AD-related genes, including Pdgfra and Camp,
but also suppressed expression of the pro-fibrotic gene Spp1
at the infection site (Figures 6H and S5C). The reactive adipogen-
esis responses, including enhanced adipocyte hyperplasia and
cathelicidin protein production, upon infection were enhanced
in SB-treated mice compared with control mice (Figure 6I). In
addition, to inhibit TGFBR specifically in dFBs, we generated
conditional heterozygous deletion of Tgfbr2 by crossing
Tgfbr2flox/flox mice to Pdgfra-cre (Tgfbr2flox/+Pdgfra-cre) mice
(Figure 6J). No homozygous Tgfbr2flox/floxPdgfra-cre offspring
were generated despite extensive breeding, and thus experi-
ments were conducted only with heterozygous offspring. dFBs(E) Flow-cytometry plots of Sca1 and SMA (top) or overlaid histogram of Sca1
(representative of n = 3 per group).
(F and G) Quantification of the gMFI of the Sca1 or SMA expression shown in (E
(H and I) Pparg1 or Spp1 mRNA expression in dFBs treated with SB or DMSO c
(J) Phase-contrast images of dFBs differentiated into adipocytes in the presence
(K) Camp mRNA expression in undifferentiated or adipocyte-differentiated dFBs
(L) Inhibition of TGFBR by SB restored the antimicrobial activity of E14 dFBs, as s
All error bars indicate mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 (one-way
130 Immunity 50, 121–136, January 15, 2019isolated from Tgfbr2flox/+Pdgfra-cre mice expressed 50%
less Tgfbr2 mRNA than WT dFBs (Figure S5D). Tgfbr2flox/+
Pdgfra-cre dFBs were less responsive to exogenous TGF-b2
treatment, as shown by an impaired induction of profibrotic
genes, including Ctgf, Acta2, and Spp1 (Figures 6K and 6L).
Importantly, when mice were subjected to S. aureus infection,
the fibrotic response in the infected skin was significantly
reduced in comparison with that of WT controls (Figure 6M).
Furthermore, more lipid droplets and cathelicidin protein were
detected in the infected Tgfbr2flox/+Pdgfra-cre dermis than in in-
fectedWT controls (Figure 6N). Overall bacterial abundance was
lower, but not statistically significant, in the infected skin of
Tgfbr2flox/+Pdgfra-cre mice than in WT controls (Figures S5E–
S5G), suggesting that heterozygous deletion of Tgfbr2 in Pdgfra+
dFBs might not be sufficient to drive a clinical phenotype. These
changes demonstrate that TGF-b critically drives age-depen-
dent loss of the innate antimicrobial function of the skin.
TGF-b Promotes Loss of Adipogenic and Antimicrobial
Defense Function of Primary Human Dermal Fibroblasts
Todeterminewhether ourobservations inmicemightalsobe rele-
vant to humans, we evaluated dWAT in human skin samples
(Caucasian; non-obese) from neonates (gestational weeks [GW]
29–38), young adults (18–25 years of age), mid-age adults (50–
65 years of age), and elderly donors (>75 years of age). Neonatal
skin, eitherpreterm (GW29–32)or full term (GW38–40), contained
a large volume of dWAT and a thin dermis, whereas in adulthood
dWATvolumebecamegradually reduced andwas eventually lost
in mid-age and elderly skin samples (Figures 7A and S6A). A
similar trend of dWAT loss during adulthood was also observed
in human skin biopsies (Chinese; non-obese) collected from
young children (2–6 years of age), young adults (18–25 years of
age), and mid-age adults (50–65 years of age) (Figure S6B).
Similar to that in mouse skin, the mRNA expression of PREF1 or
human CAMP was significantly higher in human neonatal skin
than inmid-age or elderly skin samples (Figures 7B andS6C). Im-
munostaining of human skin sections for the human cathelicidin
peptide LL-37 showed that it was abundantly expressed in
neonatal dermal ADs but not in the larger ADs in aged skin (Fig-
ure S6D). dWAT loss in adulthood coincided with an increase in
dermal thickness, fibrogenesis (as measured by collagen stain-
ing), and COL1A1 mRNA upregulation (Figures 7A, S6A, and
S6E). In elderly human skin, similar to 2-year-old mouse skin, a
decrease in dermal thickness, collagen content, and COL1A1
mRNAexpressionwasobserved (Figures7A,S6A, andS6E), sug-
gesting that prolongedactivation of dFBsmight eventually lead to
loss of cells’ pro-fibrogenic function in elderly skin.
To determinewhether TGF-b can inhibit adipogenic function of
human neonatal dFBs, we differentiated primary neonatal dFBs
isolated from five donors into adipocytes with or without TGFBR(bottom) in PDGFRA+THY1+ dFBs treated with TGFBR inhibitor SB431542
) (n = 3 per group).
ontrol for 2 days (n = 3 per group).
of SB or DMSO control (representative of n = 3 per group). Scale bars, 100 mm.
treated with SB or DMSO control (n = 3 per group).
hown by CFU counts of USA300 or SA113 growth at 20 hr (n = 3–5 per group).
ANOVA). Please also see Figure S5.
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inhibitor or recombinant TGF-b2. Neonatal dFBs from three do-
nors had high adipogenic capacity and highly expressed CAMP
and FABP4 mRNA, both of which could be completely inhibited
with TGF-b2 treatment (Figures S7A and 7C). In contrast, dFBs
isolated from the other two neonatal donors had low basal adipo-
genic capacity but became highly adipogenic and expressed
high CAMP and FABP4 mRNA when TGFBR inhibitor (SB) was
added (Figure S7A and Figure 7C). Adipogenic capacity posi-
tively correlated with PPARG mRNA expression in undifferenti-
ated cells before or after SB treatment (Figure 7D).
To define the role of TGF-b in controlling the pro-adipogenic
and pro-fibrotic functions of human dFBs, we next focused on
the neonatal dFBs with low basal adipogenic capacity. Under
basal conditions, these cells had a notable fibrotic morphology,
characterized by stratification and clustering of cells into
aggregates (Figure 7E), and this phenotype was further exacer-
bated upon treatment with TGF-b2, but was potently diminished
upon treatment with SB (Figure 7E). Flow-cytometry analysis for
SMA expression revealed that untreated cells were composed of
mixed populations with low, medium, and high expression of
SMA, and TGFBR inhibitor treatment shifted these cell popula-
tions to mostly an SMAlo state, whereas TGF-b2 treatment
shifted them toward mostly an SMAhi state (Figure 7F). These
cells expressed low basal PPARG mRNA and high ACTA2 and
CTGF (fibrotic gene) mRNA, and recombinant TGF-b2 further
decreased PPARG and increased ACTA2 andCTGF expression,
whereas SB treatment strongly increased PPARG and almost
completely suppressed CTGF expression (Figures S7B and
S7C). Thus, by default, these cells were weakly adipogenic,
and treatment with TGFBR inhibitor restored their adipogenic
function and ability to express CAMP (Figures 7E and S7C).
These results demonstrate that the endogenous TGF-b pathway
is constitutively active in neonatal human dFBs with low basal
adipogenic capacity and drives them to shift from a pro-adipo-
genic to a pro-fibrotic phenotype. Furthermore, antimicrobial as-
says using conditioned medium collected from undifferentiated
and differentiated human neonatal dFBs treated with SB demon-
strated that only differentiating adipocytes treated with TGFBR
inhibitor significantly suppressed growth of two S. aureus
strains, SA113 and USA300 (Figure 7G). In addition, inhibition
of TGFBR in primary adult dFBs isolated from four mid-age adult
donors showed a significant decrease in mRNA expression ofFigure 6. Inhibition of TGFBR Function Boosts dFBs Adipogenic Poten
(A) pSMAD2/3 immunostaining of skin sections from mice at the indicated age (r
(B and C) Measurement of serum concentrations of TGF-b2 (B) or TGF-b1 (C) in
(D and E) C57BL6WTmice (2 months old, male) were treated i.d. with DMSO (con
PCR (E) analyses as indicated (representative of n = 5–6 per group).
(F) Representative skin-lesion pictures of 1-year-old C57BL6 mice infected with
(G) Bacterial CFU count was measured from the infection edge or center area at
(H) Camp and Spp1 mRNA expression in S. aureus-infected skin (n = 3–5 per gro
(I) Representative BODIPY staining or cathelicidin (CAMP) staining in infected sk
(J) Conditional heterozygous Tgfbr2 deletion in Pdgfra+ fibroblasts, Tgfbr2flox/+Pd
cre mice.
(K and L) Primary mouse dFBs (WT or Tgfbr2 flox/+Pdgfra-cre) were treated with inc
heatmap (K) or bar graph for Spp1 (L) (n = 3 per group).
(M andN)WT or Tgfbr2 flox/+Pdgfra-cremice were infected i.d. with S. aureus. (M) m
per group). (N) Skin biopsies were subjected to BODIPY staining or cathelicidin s
with DAPI (blue).
All error bars indicate mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 (one-way
132 Immunity 50, 121–136, January 15, 2019CTGF and COL1A1 and an increase in PPARG expression (Fig-
ure 7H), suggesting that the TGF-b-mediated switch from pro-
adipogenic to pro-fibrotic also occurs in human adult cells.
Together, these results are consistent with observations in
mice and demonstrate that TGF-b drives loss of the adipo-
genic-antimicrobial function of primary human dFBs.
DISCUSSION
Effective defense against S. aureus infections relies on a proper
immune response from skin-resident cells, including adipogenic
dFBs (Zhang et al., 2015) and lymphoid and myeloid immune
cells, such as T lymphocytes, neutrophils, and macrophages
(Dillen et al., 2018; Feuerstein et al., 2015; Miller et al., 2006). It
is well established that myeloid-derived innate and adaptive im-
munity is deficient early in life (Futata et al., 2012; Georgountzou
and Papadopoulos, 2017; Shaw et al., 2013), suggesting that the
non-myeloid-resident cells, such as adipogenic dFBs, could
provide critical host defense against invasive S. aureus infec-
tions, especially in early life. However, age-related changes in
the innate immune function of adipogenic dFBs have been
unexplored.
We have shown that PDGFRA+THY1hi dFBs responded to
infection by producing cathelicidin through reactive adipogene-
sis, and loss of this antimicrobial response led to increased sus-
ceptibility to S. aureus infection. We have also shown that
neonatal skin immunity was composed of highly adipogenic
PDGFRA+THY1hi dFBs and a large volume of immature dermal
fat that highly expressed cathelicidin. These results suggest
that adipogenic dFBs and immature fat layers could function
as critical antimicrobial protective components in neonatal skin
immunity, when myeloid and lymphoid immune systems are
not yet mature. During postnatal development and in adulthood,
the PDGFRA+THY1hi dFB population, immature fat, and the adi-
pogenic potential of dFBs became progressively lost as the
myeloid immune system matured, suggesting that the latter
compensates for the loss of innate immune function of adipo-
genic dFBs.
To identify the underlying mechanisms for age-dependent
changes in adipogenic function of dFBs, we cultured primary
dFBs isolated from mouse skin at different ages and observed
a drastic pro-adipogenic-to-pro-fibrotic switch that was agetial and Enhances Resistance to Skin Infection
epresentative of n = 3 per group).
mice at the indicated age (n = 3–6 per age group).
trol) or SB daily for 5 days, and skin samples were collected for H&E (D) or qRT-
S. aureus and then treated i.d. with DMSO or SB (n = 5 per group).
day 3 (n = 5 per group).
up).
in (n = 3–5 per group). Nuclei were stained with DAPI (blue).
gfra-cre, was achieved through the breeding of Tgfbr2flox/flox mice with Pdgfra-
reasing doses of TGF-b2, and induction ofCtgf, Acta2, and Spp1 is shown in a
RNA expression of profibrotic gene Spp1 in infected skin (ratio to Tbp) (n = 3–5
taining as indicated (representative of n = 3–5 per group). Nuclei were stained
ANOVA). Scale bars, 100 mm. Please also see Figure S1.
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Figure 7. TGF-b Promotes Loss of Adipogenic and Antimicrobial Defense Function of Primary Human Dermal Fibroblasts
(A) Representative collagen-trichrome-staining images of human back skin sections from neonates (pre-term, gestation weeks [GW] 29–32; full-term, GW38–40),
young adults (18–25 years of age), mid-age adults (50–65 years of age), and elderly adults (>75 years of age). All subjects were white Caucasians (n = 3–6 per age
group). dWAT is highlighted by red lines. Scale bars, 100 mm.
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dependent: neonatal dFBs were highly adipogenic and potently
inhibited bacterial growth, whereas adult cells gained pro-
fibrotic features, and both embryonic and adult dFBs had low
adipogenic capacities and were not able to control bacterial
growth. On the basis of RNA-seq analysis, we hypothesized a
key role for TGF-b and confirmed it by reproducing the pheno-
type of adult or aged cells after treatment of neonatal dFBs
with recombinant TGF-b2 and by rescuing loss of function in em-
bryonic, adult, or aged dFBs after administration of a pharmaco-
logical inhibitor of TGFBR or via targeted genetic deletion.
Administration of TGF-b inhibitor or targeted heterozygous dele-
tion of Tgfbr2 in Pdgfra+ dFBs was also effective in vivo at
restoring the reactive adipogenesis-antimicrobial defense func-
tion of dFBs in adult mice. Although the pro-fibrotic (Lakos
et al., 2004) and anti-adipogenic (Choy and Derynck, 2003) func-
tions of TGF-b pathways are already known, our results identify
these fundamental functions of TGF-b as a key regulatory mech-
anism controlling the innate antimicrobial function of dFBs.
In vitro, Tgfb2 was the most abundant TGF-b isoform ex-
pressed by dFBs, and its expression correlated with the age-
related loss of adipogenic potential. TGF-b2 was found to be
three to ten times more potent than TGF-b1 in triggering the adi-
pogenic-to-pro-fibrotic switch in neonatal dFBs. In vivo, circu-
lating TGF-b2 concentrations in mouse serum were high early
in life (from P1 to P3 weeks) and then declined from adulthood
through aging, whereas circulating TGF-b1 concentrations
were low in neonates and became elevated with advancing
age. We posit that a high serum concentration of TGF-b2 early
in life might drive the rapid loss of adipogenic function of
neonatal dFBs during postnatal development, whereas a decline
in TGF-b2 serum concentration later in life might be compen-
sated by rising TGF-b1. TGF-b2 can also be produced by other
skin cell types, such as hair follicle keratinocytes and dermal
papilla cells (Hibino and Nishiyama, 2004; Soma et al., 2002),
and TGF-b2 could synergize with TGF-b1, which is abundantly
produced by immune cells, such as macrophages (Keophiphath
et al., 2009) and regulatory T cells (Bommireddy and Doetsch-
man, 2007). Alternatively, endogenous production of TGF-b
from adipocytes or surrounding stromal cells could provide a
source for autocrine or paracrine suppression of adipocyte pro-
genitors. Future studies will be needed to determine the cellular
source of these TGF-b ligands.
Dermal fibroblasts are the major mesenchymal cell type in the
skin, and these cells exhibit considerable functional diversity,
which was also observed in our culture system. Primary mouse
neonatal dFB cultures appeared highly homogeneous (>90%
of cells were Sca1hiSMAlo), whereas adult dFBs appeared het-
erogeneous with mixed populations of Sca1hi–lo and SMAlo–hi(B) qRT-PCR analyses of CAMP mRNA expression (ratio to housekeeping HPRT
(C) Human dFBs isolated from five neonatal donors were differentiated to adipocy
expression of the indicated genes in undifferentiated or differentiated cells with h
(D) qRT-PCR analysis of PPARGmRNA expression in neonatal dFBs (with high or
(E–G) Primary human neonatal dFBs (with low basal AC) were differentiated into
Phase-contrast images (representative of n = 3 per group). Scale bars, 200 mm. (F)
with SB or TGF-b2 (representative of n = 3 per group). (G) CFU count of S. au
differentiated cells as indicated (n = 3–5 per group).
(H) Primary adult human dFBs were isolated from four mid-age donors’ back ski
dFBs treated with vehicle control or TGFBR inhibitor (n = 3 or 4 per group).
All error bars indicate mean ± SEM *p < 0.05, **p < 0.01, ***p < 0.001 (one-way A
134 Immunity 50, 121–136, January 15, 2019cells in culture. The Sca1loSMAhi dFBs harbored a myofibro-
blast-like gene signature (Hinz et al., 2012; Lee et al., 2010)
and exhibited higher mRNA expression of pro-fibrotic genes
(such as Acta2, Ctgf, and Spp1) and lower expression of
pro-adipogenic expression (such as Pref1 and Pparg1) than
Sca1hiSMAlo neonatal dFBs. This adipogenic-to-pro-fibrotic
switch by adult cells could be reversed upon inhibition of TGFBR,
suggesting that the plasticity between distinct phenotypic sub-
populations of dFBs might be controlled by TGF-b. Analogous
two-way conversion between myofibroblasts and adipogenic fi-
broblasts has been reported in several recent studies using ge-
netic lineage-tracing tools in mice. In the mouse model of
idiopathic pulmonary fibrosis, lung lipogenic fibroblasts have
been observed to differentiate into myofibroblasts during early
fibrosis formation, and later, during resolution of fibrosis, the
population of newly formed myofibroblasts switches back to
lipogenic fibroblasts (El Agha et al., 2017). In the skin, myofibro-
blasts that accumulate in the bleomycin-induced mouse model
of scleroderma originate from Adipoq-positive intradermal pro-
genitors (Marangoni et al., 2015). Furthermore, myofibroblasts
formed during early skin wound healing give rise to new adipo-
cytes that regenerate de novo during later stages of wound
healing around de novo hair follicles (Plikus et al., 2017). Highly
relevant to our work, these studies suggest that the pool of adi-
pogenic fibroblasts in the skin or lung can switch between a pro-
fibrotic phenotype (such as myofibroblasts) during injury and a
pro-adipogenic phenotype during injury resolution. Our results
here suggest that TGF-b might be the key factor that regulates
this plasticity between distinct phenotypic subpopulations of
dFBs. Future studies are needed to identify the endogenous
TGFBR inhibitor that converts pro-fibrotic dFBs to the adipo-
genic lineage.
In conclusion, these observations have uncovered that an
age-dependent activation of the TGF-b pathway attenuates
adipogenic function of dermal fibroblasts and promotes a subse-
quent loss of antimicrobial defense by dermal fat. This work pro-
vides insights into how activation of TGF-b negatively affects
skin defense against infection and suggests that small molecules
that suppress TGFBR might be an effective therapeutic to com-
bat skin infections.STAR+METHODS
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STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Rabbit anti-CRAMP University of California San Diego Dr. Richard Gallo
Rabbit anti-LL37 University of California San Diego Dr. Richard Gallo
goat anti-COLIV Millipore Cat# AB769; RRID: AB_92262
Mouse anti-FABP4 Abcam Cat# ab188387
Rabbit anti-Phospho-SMAD2, 3 Cell Signaling Cat# 8828; RRID: AB_2631089
Rabbit anti-SMAD2/3 Abcam Cat# ab202445
rabbit anti-phospho-AKT antibody Cell Signaling Cat# 4060; RRID: AB_2315049
mouse anti-AKT Cell Signaling Cat# 4691; RRID: AB_915783
anti-mouse CD16/32 eBioscience Cat# 14016185; RRID: AB_467134
PECy7 anti-CD45 BioLegend Cat# 147704; RRID: AB_2563536
PerCP-Cy5.5 anti-CD31 BioLegend Cat# 102522; RRID: AB_2566761
PE anti-THY1 BioLegend Cat# 105308; RRID: AB_313179
APC anti-PDGFRA eBioscience Cat# 17140181; RRID: AB_529482
BV605 anti-Sca1 BioLegend Cat# 108133; RRID: AB_2562275
AF488 anti-SMA eBioscience Cat# 53976082; RRID: AB_2574461
APC anti-CD4 Biolegend Cat# 100516; RRID: AB_312719
BV510 anti-CD8a Biolegend Cat# 100752; RRID: AB_2563057
APC-Cy7 anti-TCRb Biolegend Cat# 109220; RRID: AB_893624
PE anti-TCRdg eBioscience Cat# 12571182; RRID: AB_465934
PerCP-Cy5.5 anti-CD45.2 Biolegend Cat# 109828; RRID: AB_893350
PECy7 anti-CD11B Biolegend Cat# 101216; RRID: AB_312799
FITC anti-Ly6G eBioscience Cat# 11593182; RRID: AB_465314
PE anti-F4/80 eBioscience Cat# 12480182; RRID: AB_465923
APC anti-CD11C Biolegend Cat# 117310; RRID: AB_313779
AF700 anti-MHCII eBioscience Cat# 56-5321-82; RRID: AB_494009
zombie violet viability dye Biolegend 423114
Bodipy ThermoFisher Scientific D3922
Bacterial and Virus Strains
S. aureus USA300 University of California San Diego Dr. Victor Nizet
S. aureus SA113 University of California San Diego Dr. Victor Nizet
Biological Samples
Mouse skin, spleen, blood samples University of California San Diego,
Animal Facility
N/A
Neonatal human skin samples International Institute for Advancement
of Medicine (IIAM)
N/A
Adult human skin samples University of California San Diego,
Dermatology clinics
N/A
Chemicals, Peptides, and Recombinant Proteins
SB431542 Selleckchem S1067
SIS3 Selleckchem S7959
Wortmannin EMD Millipore 9951
3-Isobutyl-1-methylxanthine (IBMX) SIGMA-ALDRICH I5879
Indomethacin SIGMA-ALDRICH I8280
Dexamethasone SIGMA-ALDRICH D4902
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
Insulin SIGMA-ALDRICH 91077C
DMEM, high glucose Thermo Fisher Scientific (Life Technologies) 11965118
Antibiotic-Antimycotic Thermo Fisher Scientific (Life Technologies) 15240062
Glutamax Thermo Fisher Scientific (Life Technologies) 35050-061
Recombinant mouse TGFb1 R&D Systems 7666-MB-005
Recombinant mouse TGFb2 R&D Systems 7346-B2-005
PureLink RNA Mini Kit Thermo Fisher Scientific (Life Technologies) 12183025
Collagenase D from Clostridium histolyticum Roche 11088882001
Deoxyribonuclease I from bovine pancreas,
Type IV, lyophilized powder
SIGMA-ALDRICH D5025-150KU
RNase-free DNase Set QIAGEN 79254
iScript cDNA synthesis kit Bio-Rad 1725038
2x SYBR Green qPCR Master Mix Bimake B21202
Super Script II Reverse Transcriptase Invitrogen 18064014
KAPA HiFi Hotstart ReadyMix Kapa Biosystems KK2601
AMPure XP beads Beckman Coulter A63881
Critical Commercial Assays
Gomori Trichrome green collagen staining kit ThermoFisher Scientific 87021
Hydroxyproline assay kit BioVision K555-100
Mouse TGF-beta 1 ELISA R&D Systems DY7346-05
Mouse TGF-beta 2 ELISA R&D Systems DY7346-05
Intracellular Fixation & Permeabilization
Buffer Set
eBioscience 88-8824-00
Nextera DNA Sample Preparation kit Illumina FC-121-1030
NextSeq 500 High Output Kit v2 – 75 cycles Illumina FC-404-2005
Deposited Data
RNA-seq data of cultured E14 2 month
dermal fibroblasts
NCBI Gene Expression Omnibus (GEO) GEO: GSE121460
Experimental Models: Cell Lines
Primary mouse or human dermal fibroblasts This study Isolated from mouse or human skin dermis
Experimental Models: Organisms/Strains
Campflox/flox mice This study Dr. Richard Gallo
Pdgfra-cre mice Jackson laboratory 013148
Adipoq-cre mice Jackson laboratory 028020
Tgfbr2flox/flox Jackson laboratory 012603
Oligonucleotides
Mouse primers for RTqPCR Integrated DNA Technologies (IDT) See Table S1 for primer sequences
Human primers for RTqPCR Integrated DNA Technologies (IDT) See Table S2 for primer sequences
Software and Algorithms
GraphPad Prism GraphPad Software, Inc. N/A
FlowJo V10 FlowJo LLC N/A
Ingenuity pathway analysis QIAGEN N/A
Bowtie http://bowtie-bio.sourceforge.net/
manual.shtml
RSEM https://github.com/deweylab/RSEM
Next maSigPro https://www.bioconductor.org/packages/
release/bioc/html/maSigPro.html
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to andwill be fulfilled by the LeadContact, Richard L.
Gallo (rgallo@ucsd.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals and animal care
All animal experiments were approved by the University of California, San Diego (UCSD), Institutional Animal Care and Use commit-
tee. C57BL/6 wild-type mice were originally purchased from Jackson laboratory, and were then breeded and maintained in animal
facility of UCSD. For aging mouse model, dorsal skin biopsies were collected from C57BL/6 wild-type male mice with various ages
(E14, P1, 3W, 2 months and 1 year old). Pdgfra-cremice (Stock No: 013148), Adipoq-cremice (Stock No: 028020) and Tgfbr2flox/flox
mice (Stock No: 012603) were originally purchased from Jackson laboratory then breeded andmaintained in animal facility of UCSD.
Campflox/floxmice, in which exon 2 and exon 4 of Camp genewere flanked by LoxP sites, were generated byOzgene (Bentley DC,WA,
Australia) Fibroblasts or adipocyte specific deletion of Camp were generated by breeding Campflox/flox mice with Pdgfra-cremice or
Adipoq-cre mice respectively. Tgfbr2 specific deletion in fibroblasts was achieved by breeding Tgfbr2flox/flox mice with Pdgfra-cre
mice. Probably due to early embryonic lethality, we were not able to get the homozygous deletion of Tgfbr2 in fibroblasts
(Tgfbr2flox/flox;Pdgfra-cre) over more than one year of breeding, so the heterozygous deletion of Tgfbr2 in fibroblasts (Tgfbr2flox/+;
Pdgfra-cre) was used instead as the Tgfbr2 heterozygous deletion model to study the role of TGFBR pathway in the infection trig-
gered dermal adipogenesis-antimicrobial response. Dorsal skin biopsies around the same area were collected from mice with
various ages for analysis to control the consistency of the tissue site collected over the whole lifetime of the mouse
Mouse model of S. aureus skin infection
Skin infection experiments were done as described before (Zhang et al., 2015). Staphylococcus aureus strain USA300 (MRSA) was
used for in vivo infection. In brief, the backs of sex-matched and age-matched adult wild-type or indicated strain of mutant mice were
shaved and hair removed by chemical depilation (Nair) then injected subcutaneously with 100 mL of a mid-logarithmic growth phase
of S. aureus (1x 107 CFU of bacteria) in PBS. Mice were sacrificed after day 3 and skin biopsy covering the infection area was har-
vested. Skin biopsies were homogenized in 1 mL Trizol (for RNA) or PBS (for CFU counting) with 2 mm zirconia beads in a mini-bead
beater 16 (Biospect, Bartlesville, OK). To count CFU, homogenized skin samples were serially diluted, plated onto Tryptic Soy Agar,
and enumerated after 18 hr to quantify the CFU per gram of tissue. For administration of TGFBR inhibitor, SB431542 (0.125 mg in
100uL of 2% DMSO + 30% PEG300 + PBS) or vehicle control was injected intradermally within the infection site at 24 hr and
48 hr post infection and skin biopsies were collected at day 3 post infection for RNA extraction or CFU count as described above.
For all animal studies, animals were randomly selected without formal pre-randomization and quantitative measurements were done
without the opportunity for bias.
METHOD DETAILS
Chemicals, antibodies and dyes
IBMX (3-Isobutyl-1-methylxanthine), dexamethasone, indomethacin, and recombinant human insulin were purchased from Sigma-
Aldaich (St. Louis, MO). SB431542 and SIS3 were purchased from Selleckchem (Houston, TX). Wortmannin was purchased from
EMDMillipore (Billerica, MA). Rabbit anti-CRAMP and rabbit anti-LL-37 antibodies were made from our lab as described previously
(Zhang et al., 2015; Zhang et al., 2016); goat anti-COLIV, mouse anti-FABP4 and rabbit anti-SMAD2/3 antibodies are from Abcam
(Cambridge, MA); Lipid dye bodipy is from Molecular Probes (Eugene, OR). Rabbit anti-Phospho-SMAD2, 3, rabbit anti-phospho-
AKT antibody and mouse anti-AKT antibody were purchased from Cell Signaling (Danvers, MA). Recombinant mouse TGFb1 and
TGFb2 were purchased from R&D Systems (Minneapolis, MN).
Human skin sample collection
Fresh adult human (Caucasian) full thickness skin biopsies, from the back of healthy and non-obese male donors between 1890
years of age, were collected by the Dermatology clinics, University of California SanDiego. Fresh adult human (Chinese) full thickness
skin biopsies were collected by Hospital for skin disease, Institute of Dermatology, Chinese Academy of Medical Science and Peking
Union Medical College. All sample acquisitions, were approved and regulated by the University of California San Diego Institutional
Review Board (reference number 140144) or by Institute of Dermatology, Chinese Academy of Medical ScienceMedical Ethics Com-
mittee (reference number 2012003). The informed consent was obtained from all subjects prior to skin biopsies. Fresh neonatal full
thickness skin samples, from the back of neonatal donors, were obtained from the international institute for advancement ofMedicine
(IIAM; Exton, PA). The informed consent was obtained from parent of neonatal donor prior to skin collection. All human biopsies were
taken from the back skin, where it is relatively protected from sun exposure compared to other regions such as face and neck of the
body. Upon collection, these samples were directly fixed with PFA then proceed for either paraffin embedding or OCT embedding for
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Histology, collagen trichrome staining and immunohistochemistry (IHC)
Paraffin embedding and sectioning was performed by theMoores cancer center histology core at UCSD. For OCT embedding, tissue
biopsies were first fixed with 4% PFA for 2 hours then cryoprotected by sucrose for 48 hours prior to being embedded in OCT
compound and stored in 80C. Histological analysis was performed using either paraffin sections or frozen sections by
Hematoxylin-Eosin (H&E) staining. Collagen was stained by the Richard-Allan Scientific Gomori Trichrome green collagen staining
kit (ThermoFisher Scientific, Waltham, MA, USA). Elastic staining (Thermo Fisher Scientific, Waltham, MA, USA) and hydroxyproline
assay (BioVision) were performed on human or mouse tissues according to manufacturer’s instructions. For IHC, fixed and permea-
bilized tissue sections were blocked with Image-iT FX reagent (invitrogen) before incubating with primary antibodies followed by
appropriate 488- or Cy3-coupled secondary antibodies. Nuclei were counter-stained with DAPI. All images were taken with an
Olympus BX41 microscope (widefield) or Zeiss LSM510 confocal microscope as indicated.
Primary dermal fibroblast isolation and culture
For neonatal mouse dorsal skin, epidermis was first removed from the dermis by overnight dispase digestion as described before,
and for adult skin hair was first removed by clipper then cut into 5mmwide strips prior to dispase digestion. The dermis was then cut
into small pieces (1 mm) by scalpel then digested with 2.5 mg/mL Collagenase D and 30 ng/mL DNase1 for 2 hours at 37C with
constant rocking to release dermal fibroblasts. Cells mixture was then filtered through 30 mm filter into single cell suspension then
treated with red blood cell lysis buffer. Isolated dermal fibroblasts were cultured in growth medium (DMEM supplemented with
10% FBS, glutamax and antibiotics-antimicotics) in a humidified incubator at 5% CO2 and 37C under sterile conditions. Fresh
medium was replenished daily to remove debris or dead cells. Primary cells were then trypsinized within 3 days and replated at
5 3 104/mL for in vitro assays, and only passage 1 cells were used for experiment. To induce adipocyte differentiation, two day
post-confluent dFB were switched to adipocyte differentiation medium containing 2 mM Dexamethasone, 250 mM IBMX, 200 mM
Indomethacin and 10 mg/mL recombinant human insulin. Fresh differentiation medium was changed at day 2, 4, and 7 during the
differentiation time course.
Flow cytometry and analysis (FACS)
FACS analysis of primary dermal fibroblasts was modified from previously reported method for adipogenic fibroblasts (Chia et al.,
2016; Rivera-Gonzalez et al., 2016). Briefly, freshly isolated dFB from mouse skin or primary cultured of dFB first were stained
with zombie violet viability dye (BioLegend, 423114) to stain dead cells. Cells were then blocked with anti-mouse CD16/32
(eBioscience, 14016185), followed by staining with an antibody cocktails containing PECy7-CD45 (BioLegend, 147704), PerCP-
Cy5.5-CD31 (BioLegend, 102522), PE-THY1 (BioLegend, 105308), APC-PDGFRA (CD140a) (eBioscience, 17140181) and BV605-
Sca1 (BioLegend, 108133). Stained cells were then fixed and permeabilized using the intracellular fixation and permeabilization
buffer set (eBioscience), then intracellular SMA was stained by AF488-SMA (eBioscience, 53976082). For FACS staining of T cell
populations, cells were stained with an antibody cocktail including APC-CD4 (Biolegend, 100516), BV510-CD8a (Biolegend,
100752), APC-Cy7-TCRb (Biolegend, 12-5711-82), PE-TCRdg (eBioscience, 12-5711-82), and PerCP-Cy5.5-CD45.2 (Biolegend,
109828). For FACS staining of other myeloid immune cell panel, cells were stained with an antibody cocktail including PECy7-
CD11B (BioLegend, 101216), FITC-Ly6G (eBioscience, 11593182), PE-F4/80 (eBioscience,12480182), APC-CD11C (BioLegend,
117310), AF700-MHCII and (eBioscience, 56532182) FACS analysis for protein expression of each cell marker was performed by
the BD FACSCanto RUO machine and analyzed by FlowJo V10 software. Dead cells stained positive with zombie violet dye were
excluded from the analyses.
Reverse transcription-quantitative PCR (RTqPCR) analyses
Total cellular RNA was extracted using the PureLink RNA isolation kit with RNase-free DNase1 digestion to remove genomic DNA
contamination (QIAGEN) and 500 ng of RNAwas reverse transcribed to cDNA using iScript cDNA synthesis kit (Bio-rad). Quantitative,
real-time PCR was performed on the CFX96 real time system (Bio-rad) using SYBR Green Mix (Bimake, Houston, Tx). All of the
primers used with SYBR green were designed to span at least one exon to minimize the possibility of nonspecific amplification
from the genomic DNA. The expression of Tbp gene (TATA-Box Binding Protein) was used as a house keeping gene to normalize
data for the expression of mouse genes, and HPRT was used as a house keeping gene for the expression of human genes. Specific
primer sequences are shown in Table S1 (mouse genes) and Table S2 (human genes).
Immunoblotting analyses
10ul of cell mediumwas separated on a 10%–20%Tris-Tricine precast gel (Biorad), transferred to PVDFmembrane (Biorad), followed
by immunoblotting using indicated primary antibodies followed by fluorescent secondary antibodies (LICOR) and imaging using fluo-
rescent Odyssey System (LICOR).
TGFb1 and TGFb2 ELISA
Mouse TGFb1 or TGFb2 ELISA Kit was purchased from R&D Systems (Minneapolis, MN) and TGFb1 orTGFb2 concentrations in
conditioned medium from primary mouse dermal fibroblasts or mouse serum were determined according to manufacturer’s
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In vitro bacterial killing assay
Antibiotic free and phenol-red free conditioned medium was collected from differentiating dermal fibroblasts as described before
(Zhang et al., 2015). The conditioned medium (100 mL) was then mixed with 105/ml CFU (colony forming unit) of indicated bacterial
strain in 96 well tissue culture microtiter plates and incubated at 37C for 10 48 hr prior to plating for CFU counting. The optical
density at 595 nm (OD595) was also measured every 24 hours by a spectrometer.
Sample preparation for RNA-seq
Primary dermal fibroblasts, isolated from dorsal skin of mouse at E14, E17, P1, 3 weeks and 2 months of age, were harvested at the
first passage. To enrich fibroblasts that have committed to adipocyte lineage, Sca1+ dFB were purified from P1, 3 week and 2month
dFB using the anti-Sca1microbeads kit andMACS columns and separators (Miltenyi Biotec, SanDiego, CA). Purity of cells from each
age group was greater than 90% as confirmed by FACS analyses. Total cellular RNA was extracted using the PureLink RNA isolation
kit with DNase1 digestion to remove genomic DNA contamination (Life Technologies) and 10 ng total RNA (n = 3 for each age group)
was used for SMART-seq2.
SMART-seq2
SMART-seq2 was performed as previously described with minor. Briefly, 10 ng total RNA (RIN > 9.6) was reversed transcribed using
Super Script II (Invitrogen). cDNA was pre-amplified for 10 cycles using high fidelity KAPA HiFi HotStart Ready Mix (Kapa Bio-
systems). Pre-amplified cDNAs were cleaned with AMPure XP beads (Beckman Coulter) at a 1:1 ratio and eluted with elution buffer
(QIAGEN). Tn5-mediated tagmentation was performed on 18 ng total cDNA using the Nextera DNA Sample Preparation Kit (Illumina)
at 55C for 5 minutes and deactivated with PM buffer (QIAGEN). Adaptor-ligated fragments were amplified for 8 continuous cycles
using universal Ad1 and unique Ad2.xx barcodes (IDT). Amplified PCR fragments were purified with AMPure XP beads as suggested
(Beckman Coulter). Size selected libraries were quantified using Qubit (Thermo), loaded on a High-Sensitivity DNA chip for quality
control (Agilent), and quantified using KAPA for Illumina Sequencing Platforms (Illumina). Libraries were multiplexed and sequenced
as paired-end, 43 bps on a NextSeq 500 Illumina Sequencing Platform (Illumina) (Cluster density = 252K/mm2, Clusters PF = 78.8%,
Q30 = 90.7%).
Transcript alignment, quantification and filtering
Paired-end readswere aligned to themouse genome (mm10/gencode.vM4) with bowtie (version 1.0.0) and quantified using the RNA-
seq by Expectation-Maximization algorithm (RSEM) (version 1.2.12) with the following standard parameters: rsem-calculate-expres-
sion -p $CORES-paired-end. Samples displaying > 12,000,000 aligned reads and > 77%alignment were considered for downstream
analyses. Samples were filtered and only protein-coding genes and lncRNAs expressed at minimum 1 TPM in at least one sample in
all biological replicates were considered for downstream analyses.
SMART-seq2 and IPA analyses
Differential expression dynamics across E14, E17, P1-Sca1+, 3W-Sca1+, 2M-Sca1+ samples was identified using the single-time
series, two-step regression model algorithm Next maSigPro using with the following parameters under the T.Fit, get.siggenes and
see.genes functions: alfa = 0.01, vars = ’’all,’’ rsq = 0.7, k = 7. Principle component analyses were performed using the R ggbiplot
package. Pathway and upstream regulator analyses were performed by Ingenuity pathway analysis (IPA) from QIAGEN.
QUANTIFICATION AND STATISTICAL ANALYSIS
Experiments were repeated at least 3 times with similar results. Statistical significance was determined using Student’s unpaired
two-tailed t test, or one way ANOVA multiple comparison test as indicated in the legend (*p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001).
DATA AND SOFTWARE AVAILABILITY
RNA-seq data of cultured dermal fibroblasts reported in this paper has been deposited to NCBI Gene Expression Omnibus (GEO),
GEO: GSE121460.Immunity 50, 121–136.e1–e5, January 15, 2019 e5
